Alkermes shares dip despite 'positive' trial results from schizophrenia drug

Alkermes, one of the state’s largest drugmakers, announced the results of a late-stage trial of a schizophrenia drug Thursday it calls "positive," but investors appear to have doubts about the drug’s effect on patients’ weight.